Why is this study being conducted?
The purpose of the study is to evaluate the safety and immunogenicity of a respiratory syncytial virus (RSV) mRNA vaccine candidate in adult participants 60 years of age and older. Respiratory syncytial virus is a leading cause of respiratory illness in adults (second to the flu) with no specific treatment options.
Who is eligible to participate in this study?
Men and women 60 years of age or older who:
- Are in good general health
- Have no current immunodeficiency disease/condition
- Have not had previous allergic reactions to vaccines
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be up to 6 months and participants will have about 2-3 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will have a 1 out of 2 chance of receiving the study vaccine and a 1 out of 2 chance of receiving the placebo vaccine.
You will have 1-2 scheduled phone calls for safety follow up and active surveillance contacts (phone, email or text) every two weeks.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Cassandra Balinas
To learn more about this clinical trial, please contact:
Cassandra Balinas, Clinical Trial Coordinator.
07 5678 0362 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Ltd #2023-11-1491 and GU HREC #2024/154.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials